Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bioavailability and Food Effect of AZD5718 Formulations
NCT03420092Phase 1Completed
- Sponsor
- AstraZeneca
- Start
- Feb 2018
- Primary completion
- Apr 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of atuliflapon in coronary artery disease (CAD) (6 arms), sponsored by AstraZeneca. Primary endpoints: Area under plasma concentration-time curve, Area under plasma concentration-time curve from time zero to last quantifiable concentration and 2 more. Started Feb 2018; status: completed.
02
Drugs
atuliflapon
03
Conditions
coronary artery disease (CAD)
Beyond the preview
Go deeper on NCT03420092.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03420092.